Policy & Regulation
Iktos Partners with Medicines for Malaria Venture in Anti-Malarial Drug Discovery
23 November 2022 - - French start-up company Iktos, a specialist in Artificial Intelligence for new drug design, has forged a collaboration with Medicines for Malaria Venture, a product development partnership in the field of antimalarial drug research and development, the company said.

Under this collaboration agreement, Iktos will apply its new 'DockAI' technology to expedite the discovery of novel antimalarial drug candidates.

The objective of the collaboration is to tackle a key challenge in the drug discovery process: discovery of "hits" which could be optimized to leads and candidates for clinical development.

Classical hit finding approaches usually involve screening of libraries of molecules either in vitro, or in silico, and these approaches have limitations in terms of time, cost efficiency and the limited size of the underlying screening databases.

The collaboration between Iktos and MMV will use an alternative to these classical approaches by combining Iktos' proprietary 'DockAI' innovation for ultra-large-scale virtual screening (hundred million plus molecules) with cloud-based high performance computing for a computational run.

The goal is to deliver novel hit compounds that can then ultimately be optimized into pre-clinical candidates.

Iktos' 'DockAI' approach will be applied on a therapeutic target previously identified and validated by MMV for anti-malarial drug development.

Docking simulations are widely used in the pharmaceutical industry to simulate the interaction between screening compounds and a biological target (usually a protein) to predict biological activity of a chemical compound.

Iktos' AI approach builds on this and aims to use an iterative workflow to identify the most promising hits from a very large compound database to facilitate rapid and cost-effective identification of hits.

By reducing the cost of virtual screening by a factor of 20, this approach enables the screening of ultra large compound databases, inaccessible with traditional approaches, which should increase the probability of success.

Inc. in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design.

Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya. Iktos is also developing Spaya, a synthesis planning software based upon Iktos's proprietary AI technology for retrosynthesis.


Related Headlines